$KVACF News

Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy

Medera And University Of Kansas Medical Center Announce Treatment Of First Patient In MUSIC-DMD Phase 1b Clinical Trial For Duchenne Muscular Dystrophy

Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

Medera And Novoheart Collaborate With Physician-Scientists At University Of California San Diego School Of Medicine And Mayo Clinic To Develop Mini-Heart Models Aimed At Transforming Treatment For HLHS

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Medera Showcases Interim Data From First-in-Human Gene Therapy Trial For HFpEF In Late-Breaking Presentation At Heart Failure 2025 Congress; Clinical Trial Show Favorable Safety Profile And Early Clinical Benefits With SRD-002 Gene Therapy

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing In Phase 1/2a MUSIC-HFrEF Trial Of SRD-001 Gene Therapy

Medera Completes Patient Dosing In Phase 1/2a MUSIC-HFrEF Trial Of SRD-001 Gene Therapy

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera, Inc. to Participate in Two Upcoming Investor Conferences

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.